BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT06773910
Trial Phases:	Phase II	Protocol IDs:	LUN 567 (primary) NCI-2026-01730
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	SCRI Development Innovations, LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT06773910

Summary

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose
combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC)
participants.

The main goals of this study are to:

- Evaluate the efficacy of BMS-986489 vs durvalumab

- Evaluate the safety profile of BMS-986489

Objectives

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose
combination) vs durvalumab as consolidation therapy following chemoradiotherapy in
participants with limited-stage (LS)-small-cell lung cancer (SCLC). Participants will
receive concurrent chemotherapy and radiotherapy according to standard guidelines for
treatment of LS-SCLC without progressive disease prior to randomization. Eligible
participants will be randomly assigned to receive either BMS-986489 (atigotatug +
nivolumab as a fixed-dose combination; Arm A) or durvalumab (Arm B) as consolidation
therapy. Atigotatug is a first-in-class, fully human IgG1 antibody being developed for
the treatment of SCLC. Atigotatug specifically binds to fuc-GM1 on the tumor cell.
Nivolumab is a monoclonal anti-PD-1 antibody. Combining atigotatug with another
immunotherapy may provide enhanced antitumor effects.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.